Strassen buying Ecstasy

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Strassen buying Ecstasy

In einer toxikologischen Screeninguntersuchunggab es kein Hinweis auf eine akute Intoxikation. Nach wiederholter Benzodiazepingabe bei starker Agitation und Myoklonien kam es zu einer Atemdepression, so dass der Patient intubiert werden musste. Zur Kupierung der Myoklonien und der Entzugssymptomatik waren bis zum 4. Therapietag kontinuierliche Gaben von Midazolam und Clonidin notwendig. Der Patient wurde nach 19 Therapietagen in eine psychiatrische Akutklinik verlegt. Die Therapie erfolgt symptomatisch supportiv. History and admission findings: A year-old man with known abuse of gamma-butyrolactone GBL was found with stupor and myoclonies on all extremities. Decubiti were detected on the knuckle of the right foot, on both elbows and at the rump. Investigations: Laboratory findings revealed signs of severe rhabdomyolysis and renal failure as well as elevated markers of inflammation. Other routine laboratory parameters were normal. A toxicological screening revealed no signs of an acute intoxication. Diagnosis, treatment and course: A GBL withdrawal syndrome was diagnosed. The treatment of agitation and myoclonies required repeated applications of benzodiazepines. Because of the resulting respiratory depression the patient had to be intubated. To cope with myoclonies and other symptoms of substance withdrawal we had to administer midazolame and clonidine continuously until day four. Because of acute renal failure resulting from rhabdomyolysis hemodialysis was necessary three times. After 19 days the patient was transferred to a psychiatric clinic. Conclusions: Primary care physicians treating patients with a coma of unknown cause always have to think of the possibility of GBL withdrawal. The treatment will be symptomatic. Supady uniklinik-freiburg. Year Archive Download PDF. Further Information Publication History eingereicht: Also available at. Google Scholar.

Designer drugs: mechanism of action and adverse effects

Strassen buying Ecstasy

Official websites use. Share sensitive information only on official, secure websites. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 CB 1 receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A 5-HT 2A receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death. The online version of this article The term is currently applied more widely to include substances that originate from industrial or academic research but never receive medical approval. The Internet plays a crucial role in the distribution of designer drugs and in the acquisition of information about them Miliano et al. The number of available designer drugs is constantly growing, and trends and patterns of use change over time. This poses a challenge to drug-regulatory authorities and can jeopardize public health. Designer drugs can generally be divided into the same categories as traditional drugs of abuse, namely stimulants, sedatives, dissociatives, cannabinoids, and psychedelics. However, in contrast to traditional drugs of abuse, newly emerging drugs can remain undetected by routine drug screening, and information about associated adverse effects is often scarce. Knowledge of the mechanism of action and potential clinical complications of designer drugs is key for healthcare workers who treat intoxicated patients. The present review provides an overview of the main mechanisms of action and adverse effects of currently available designer drugs. Monoaminergic stimulants, such as amphetamine, 3,4-methylenedioxymethamphetamine MDMA , and cocaine, are among the most popular drugs of abuse. MDMA is currently being investigated as a prescription drug for the treatment of posttraumatic stress disorder Amoroso and Workman ; Mithoefer et al. Stimulants modulate monoaminergic neurotransmission mainly by interacting with norepinephrine, dopamine, and serotonin 5-hydroxytryptamine \[5-HT\] transporters NET, DAT, and SERT, respectively , in addition to interacting with monoaminergic receptors and other targets. At monoamine transporters, monoaminergic stimulants act as either transporter inhibitors or substrates that mediate non-exocytotic monoamine efflux Fleckenstein et al. Different selectivity Fig. In rats, substances that are selective for DAT vs. SERT facilitate dose-dependent and abuse-related intracranial self-stimulation, indicating high abuse potential. In contrast, substances that are selective for the SERT vs. DAT depress dose-dependent intracranial self-stimulation Suyama et al. The number of available designer stimulants is constantly increasing, and their use can cause various physiological complications and mood disturbances, which are discussed in the subsequent sections for the different classes of designer stimulants. DAT vs. SERT selectivity of a variety of stimulants. Full names of the substances and source of pharmacological data are provided in the supplementary information. Correlation between reported clinical potencies and in vitro monoamine transporter inhibition of a variety of stimulants. Figure modified from Luethi and Liechti In addition to traditional amphetamines that are used both medically and recreationally, several amphetamine designer drugs without approved medical uses have become available. MDMA is by far the most popular amphetamine designer drug. It was first synthesized by Merck in as a precursor in a new chemical pathway, but it was not further investigated until many years later Freudenmann et al. MDMA has slowly found its way back into psychotherapy as a promising agent for the treatment of posttraumatic stress disorder Amoroso and Workman ; Mithoefer et al. Recently, various other, often ring-substituted amphetamine derivatives Fig. Examples of amphetamine, cathinone, and pyrovalerone derivatives. Full names of the substances are provided in the supplementary information. Most amphetamines are substrate-type monoamine releasers Rothman and Baumann ; Simmler et al. SERT, resulting in greater reinforcing effects and higher abuse liability Kuhar et al. DAT, resulting in an entactogenic effect profile and lower abuse liability Baumann et al. Para-substitution at the phenyl ring of amphetamines has been shown to shift their pharmacological profile toward more pronounced activity at the SERT vs. DAT Luethi et al. In addition to their interactions with plasma membrane transporters, amphetamines are substrates at vesicular monoamine transporters VMATs and inhibit monoamine oxidases Fleckenstein et al. Furthermore, amphetamine designer drugs have been reported to interact with various monoaminergic receptors, including serotonergic and adrenergic receptors, and trace amine-associated receptor 1 TAAR1 , which negatively modulates monoaminergic neurotransmission Di Cara et al. Numerous studies have reported the adverse effects of amphetamine, lisdexamfetamine, and methamphetamine. Among amphetamine-derived designer drugs, MDMA is the best studied. For traditional amphetamines, mainly sympathomimetic adverse effects e. Hyperthermia is a significant contributor to potentially severe adverse effects of amphetamines, including disseminated intravascular coagulation, renal failure, and rhabdomyolysis Bingham et al. The uncoupling of oxidative phosphorylation in skeletal muscle through the activation of uncoupling protein 3 UCP-3 and agonism at adrenergic receptors by norepinephrine release has previously been identified as an important contributor to MDMA-induced hyperthermia Mills et al. Many adverse effects are similar for most amphetamines, but the prevalence of some events is higher for certain specific amphetamines. A comparison of the structures and pharmacological profiles of newly emerged amphetamine designer drugs with well-studied amphetamine derivatives helps to shed light on the likelihood of these specific adverse events. Hepatotoxicity is a potentially fatal adverse effect that has been associated with the use of amphetamines, and MDMA is the designer drug that has been most frequently linked to liver injury Andreu et al. Different mechanisms may contribute to MDMA-induced hepatotoxicity, including monoamine release, hyperthermia, oxidative stress, impairments in the antioxidant response, mitochondrial dysfunction, and the formation of catechol metabolites by demethylenation Carvalho et al. Cardiotoxicity is another potential complication of amphetamine use and largely attributable to sympathomimetic activation and additionally to secondary mechanisms, such as metabolic bioactivation and hyperthermia Carvalho et al. The activation of 5-HT 2B receptors in cardiovascular tissues may potentially result in cardiac valvulopathy and is thus a concern for drugs that increase plasma 5-HT levels or directly activate 5-HT 2B receptors Elangbam ; Elangbam et al. Mild-to-moderate valvular heart disease has been observed in a population of heavy recreational MDMA users, and the 5-HT 2B receptor-mediated proliferation of cardiac valvular interstitial cells that was induced by MDMA was demonstrated in vitro Droogmans et al. The MDMA metabolite 4-hydroxymethoxymethamphetamine HMMA exhibits higher potency in stimulating vasopressin secretion; together with the excessive intake of hypotonic liquids and hyperthermia, it may cause potentially fatal hyponatremia, especially in female users likely because of effects of estrogen on vasopressin Campbell and Rosner ; Fallon et al. Monoamine depletion and reactive species contribute to the neurotoxicity of amphetamines Carvalho et al. However, despite extensive research, the extent to which different amphetamines are neurotoxic remains largely unknown. Compared with amphetamine, an increase in serotonergic toxicity has been reported for the para-chlorinated derivative 4-chloroamphetamine, likely explained by highly potent serotonergic activity coupled with considerably potent dopaminergic activity Colado et al. However, unlike other halogenated stimulants, such as 4-fluoroamphetamine, 4-chloroamphetamine never achieved popularity as a designer drug, possibly because of its well-documented neurotoxicity. Nevertheless, the widely used 4-fluoroamphetamine has been associated with various mild-to-moderate adverse effects e. A detailed review of amphetamine toxicity, including toxicological pathways that involve the formation of reactive species, the depletion of antioxidants, and microglial activation, was previously published Carvalho et al. The large-scale recreational use of synthetic cathinones is a relatively new phenomenon, although several compounds have been known for a long time. For example, the first synthesis of 4-methylmethcathinone mephedrone was published in Sanchez Several other synthetic cathinones have been investigated for their medical potential, mostly as antidepressant or anorectic agents, but only a few were ever marketed because of concerns about abuse Canning et al. Pyrovalerone derivatives represent a subgroup of synthetic cathinones based on the structure of pyrovalerone, which was developed in the s as a treatment option for lethargy, fatigue, and obesity Gardos and Cole Currently, synthetic cathinones Fig. Similar to other monoaminergic stimulants, the psychoactive effects of synthetic cathinones are primarily mediated by interactions with monoamine transporters. Many cathinones are partially or fully effective substrate-type releasers at one or several monoamine transporters, but some compounds, such as pyrovalerone derivatives, are transporter inhibitors Baumann et al. Similar to amphetamines, cathinone designer drugs also interact with several adrenergic and serotonergic receptors Luethi et al. These less potent interactions at TAAR1 may result in a higher risk of cathinone dependence compared with amphetamines. Rarely, severe adverse effects e. In vitro studies in neuronal, skeletal muscle, and hepatic cells indicated various cytotoxic mechanisms of synthetic cathinones, including mitochondrial dysfunction, glutathione depletion, oxidative stress, and apoptosis pathway activation, which are aggravated under hyperthermic conditions Dias da Silva et al. Unclear, however, is the extent to which these mechanisms contribute to clinical adverse effects of cathinones relative to sympathomimetic toxicity. Numerous cathinone-related fatalities have been reported Adamowicz et al. Various analogs of MDMA and its metabolite 3,4-methylenedioxyamphetamine MDA have become available as designer drugs, in which a dihydrobenzofuran, benzofuran, or indole group replaces the benzodioxole group Fig. Some benzofuran designer drugs were originally investigated as part of a study that examined the role of ring oxygen atoms in interactions between MDA and monoamine transporters Monte et al. Examples of stimulant designer drugs and reference substances. In addition to norepinephrine uptake inhibition, stimulant benzofuran and dihydrobenzofuran designer drugs have moderate-to-high selectivity in inhibiting 5-HT vs. Furthermore, affinity at adrenergic, serotonergic, and histaminergic receptors, partial agonism at 5-HT 2A receptors, and partial to full agonism at 5-HT 2B receptors have been reported for these designer drugs Dawson et al. The position of the alkylamine side chain is determining of DAT vs. In human transporter-transfected cells, 5-IT has been shown to be a very potent inhibiter of norepinephrine uptake, but it did not significantly induce norepinephrine efflux at a single high concentration. Additionally, 5-IT has affinity for adrenergic and serotonergic receptors and partially activates 5-HT 2A and 5-HT 2B receptors, which may result in additional perceptual psychedelic-like effects at high doses Luethi et al. Benzofuran designer drugs may cause agitation, insomnia, headache, drowsiness, dry mouth, dry eyes, bruxism, hyperthermia, tachycardia, palpitations, nausea, diarrhea, hot flashes, clonus of the hands and feet, and psychological symptoms, including visual and auditory hallucinations, depression, anxiety, panic attacks, paranoia, and psychosis Jebadurai et al. A case of drug-induced psychosis with symptoms of self-harm, paranoia, and suicidal thoughts but unremarkable physical examination was reported with the analytically confirmed presence of 6- 2-aminopropyl benzofuran 6-APB in combination with metabolites of a synthetic cannabinoid and tetrahydrocannabinol Chan et al. In addition to fatal intoxications that involve benzofurans combined with other designer drugs Adamowicz et al. Autopsy revealed white foam in the trachea, marked congestion and edema of the lungs, and congestive splenomegaly McIntyre et al. Benzofurans induce oxidative stress, disrupt mitochondrial function, and activate apoptosis cascades in vitro, but the in vivo relevance of these sequelae remain unclear Roque Bravo et al. Furthermore, 5-IT was involved in several intoxication cases with a fatal outcome within a time span of only a few months Katselou et al. Many of 5-IT-associated deaths have been attributed to cardiac arrest, to which 5-HT 2B receptor activation by 5-IT may have contributed Katselou et al. In most of the fatal and non-fatal intoxication cases, additional substances have been detected. Although the reported doses of 5-IT and 6-APB are similar, they differ in their selectivity for the dopaminergic vs. The extent to which mislabeling played a role in 5-IT intoxication remains unclear. Aminoindane designer drugs Fig. Aminoindanes are conformationally restricted analogs of amphetamine that were originally investigated as bronchodilatory, analgesic, and anti-Parkinson agents, and subsequently as drugs with psychotherapeutic value Pinterova et al. Some aminoindane designer drugs have been reported to be entactogens with lower serotonergic neurotoxicity relative to non-aminoindane entactogens Johnson et al. The desired psychoactive effects of aminoindane designer drugs include euphoria, the mild distortion of vision, time, and space, a greater intensity of perceptions and colors, empathy, and arousal Coppola and Mondola a ; Corkery et al. Similar to amphetamines, aminoindane designer drugs are monoamine transporter substrates, with relevant affinity for adrenergic, dopaminergic, and serotonergic receptors Iversen et al. Self-reported undesirable effects of aminoindane designer drugs include agitation, anxiety, panic attacks, headache, insomnia, hallucinations, and tachycardia Coppola and Mondola a. Three fatal cases were reported with confirmed MDAI intake, and serotonin syndrome could have been a factor that contributed to death Corkery et al. The likelihood of the serotonergic toxicity of aminoindanes in humans has not been investigated, but signs of serotonin syndrome were reported for a high dose of MDAI in rats Palenicek et al. Piperazine designer drugs Fig. Various therapeutic drugs have a piperazine moiety, and some piperazine designer drugs have a history of medical use. For example, 1-benzylpiperazine BZP has been investigated as an antihelmintic agent and antidepressant, and meta-chlorophenylpiperazine m-CPP is an active metabolite of different antidepressants Arbo et al. Piperazine designer drugs exert mixed effects at monoamine transporters. Both substances bind to several serotonergic, adrenergic, dopaminergic, and histaminergic receptors with submicromolar or low micromolar affinity Simmler et al. In contrast, BZP is a selective NET inhibitor with relatively weak inhibition of dopamine and 5-HT uptake, without any potent affinity at monoamine receptors Simmler et al. Adverse effects of piperazine designer drugs are mostly sympathomimetic, including agitation, insomnia, headaches, dizziness, dilated pupils, hyperthermia, tachycardia, nausea, urine retention, and inducible clonus Arbo et al. In addition to sympathomimetic toxicity, dissociative symptoms, visual and auditory hallucinations, and psychological symptoms e. Furthermore, toxic seizures were frequently observed in patients who were admitted to the emergency department after the use of BZP-containing party pills. Although there seems to be a trend toward higher concentrations being more frequently associated with seizures, they may also occur at low doses Gee et al. Other severe adverse effects of BZP include hyponatremia, severe combined metabolic and respiratory acidosis, hepatic injury, renal failure, disseminated intravascular coagulation, and rhabdomyolysis Gee et al. A case of severe hyperthermia with resultant multi-organ failure and a case of hyponatremia that led to fatal brain edema were reported for the concomitant use of piperazine designer drugs and MDMA Balmelli et al. The contribution of these individual compounds to the observed clinical manifestations remains unclear, but piperazines and MDMA may elicit additive or synergistic toxicity. In vitro, piperazine designer drugs have been reported to upregulate key enzymes of cholesterol biosynthesis, induce oxidative stress, disrupt mitochondrial function, and activate apoptosis pathways, all of which may potentially contribute to clinical toxicity Arbo et al. Derivatives of the piperidine prescription drug methylphenidate have appeared as designer drugs Fig. Similar to methylphenidate, phenidate derivatives may be used to induce euphoria or as cognitive enhancers Ho et al. Various methylphenidate-based designer drugs originated from drug development efforts and later appeared on the recreational drug market as pure compounds or in the form of branded products Bailey et al. When insufflated, the pharmacological and subjective-effect profile of methylphenidate is similar to cocaine, and phenidate derivatives may, therefore, be used as substitutes for cocaine Vogel et al. Similar to methylphenidate, methylphenidate-based designer drugs act as potent NET and DAT inhibitors that are devoid of substrate activity Luethi et al. Some less potent interactions with the SERT and adrenergic and serotonergic receptors have been reported but are not likely to play a relevant role in the psychoactive actions of most phenidate derivatives Luethi et al. Adverse effects of phenidate derivatives are similar to amphetamines and include agitation, anxiety, hypertension, tachycardia, and palpitations Bailey et al. Because of their relatively slow onset of action when taken orally, the nasal insufflation or injection of phenidate derivatives is common, especially in heavy users. Nasal pain and septum perforations after insufflation and infections after intravenous injection may occur Ho et al. The rapid onset of action after nasal or intravenous use, combined with the marked DAT vs. SERT selectivity of phenidate derivatives, has been linked to a higher risk of addiction Luethi et al. In several cases, phenidate derivatives have been analytically confirmed post-mortem, in which ethylphenidate is the most frequently detected compound Krueger et al. Many decedents had a history of heroin use, and intravenous injection was a common route of administration. In addition to phenidate derivatives, other drugs, including benzodiazepines and opioids, have been detected in most fatal cases Krueger et al. Various analogs of the anorectic agent aminorex have become available as designer drugs Fig. Aminorex was first marketed as an over-the-counter appetite suppressant in parts of Europe in the s, but it was withdrawn a few years later because of an epidemic of chronic pulmonary hypertension that was associated with many fatalities Maier et al. A comprehensive review of the history of aminorex use and the emergence of its designer drug analogs was recently published Maier et al. Aminorex and its derivative 4-MAR mediate norepinephrine and dopamine efflux in rat synaptosomes, with weak substrate activity at the SERT Brandt et al. Adverse effects of aminorex designer drugs that have been reported by users on various Internet discussion platforms include agitation, dysphoria, insomnia, amnesia, panic attacks, psychosis, hallucinations, facial spasms, dilated pupils, foaming at the mouth, dry mouth, jaw clenching, elevations of body temperature, sweating, elevations of heart rate, nausea, and restless legs Glanville et al. Pulmonary hypertension i. Designer drug analogs of aminorex have been analytically confirmed in several drug-related deaths Cosbey et al. Phenmetrazine is a reinforcing stimulant, which was previously used as an appetite suppressant before it was eventually withdrawn from the market Chait et al. Phenmetrazine-derived designer drugs Fig. Para-substituted compounds were shown to have the greatest serotonergic effects among the phenmetrazine derivatives, similar to ring-substituted amphetamine and cathinone designer drugs Luethi et al. Based on their mechanism of action, phenmetrazine designer drugs are expected to elicit stimulatory toxicity that is similar to amphetamines. However, polydrug intoxication prevented attribution of the observed effects to 3-FPM, underscored by the fact that the clinical features included some oppositional effects e. The authors of the latter case report hypothesized that the intravenous use of 3-FPM resulted in severe vasoconstriction, possibly with concomitant infection, and caused widespread ischemia Fawzy et al. Various analogs of amphetamines and cathinones with a thiophene group that replaces the phenyl ring have appeared as designer drugs Fig. Some of the thiophene designer drugs were first described in the s and elicited effects that were reported to be comparable to their phenyl ring analogs Alles and Feigen ; Blicke and Burckhalter To date, most pharmacological studies and toxicological reports involve methiopropamine MPA , the thiophene analog of methamphetamine. MPA is a quasi-equipotent inhibitor of norepinephrine and dopamine uptake and was reported to interact with various serotonergic, adrenergic, dopaminergic, N -methyl- d -aspartate NMDA , and sigma-1 receptors Iversen et al. MPA use has been associated with significant acute toxicity and psychotic, cardiovascular, and gastrointestinal symptoms, including agitation, anxiety, confusion, a lower level of consciousness, insomnia, visual hallucinations, elevations of creatine kinase, tachycardia, palpitations, chest tightness, nausea, and vomiting Daveluy et al. However, for most intoxication cases, the use of multiple substances was reported, and the extent to which MPA contributed to the reported adverse effects remains unclear. A death from isolated MPA use was described, in which cardiac arrhythmia that induced cardiovascular collapse was named as the probable cause of death Anne et al. Dopaminergic neurodegeneration and myocardial, renal, and gastrointestinal damage were observed in mice that were exposed to MPA Foti et al. Several designer drugs have appeared that do not belong to any classes that are discussed in the previous sections. Any substance that interacts with monoamine transporters may potentially be sold as a stimulant designer drug, even if it is not or only remotely chemically related to the widely used stimulant classes. While being essential for pain treatment, the non-medical use of opioids has been a public health threat for centuries and includes the recreational use of illegal substances, the abuse of prescription medications, and drug adulteration with non-pharmaceutical opioids Armenian et al. Opioids induce euphoria, anxiolysis, feelings of relaxation, and drowsiness Suzuki and El-Haddad Repeated use leads to the development of dependence. In recent years, the growing prevalence of non-pharmaceutical fentanyl, highly potent designer fentanyls, and other novel synthetic opioids Fig. Notably, fentanyl-type substances are often detected in fatalities that are presumably associated with intravenous heroin use Gladden et al. The higher potency of fentanyl and its analogs compared with classic heroin results in a higher risk of overdose, particularly when they are mistaken for heroin. Fentanyl itself was first synthesized in and has become essential and widely used for intraoperative analgesia and in the form of transdermal patches for the management of chronic pain Stanley Following its medical approval, reports of fentanyl misuse among clinicians and subsequently patients began to emerge, and several fentanyl analogs appeared on the illicit market Armenian et al. Examples of sedative designer drugs and reference substances for comparison. A detailed overview of signaling mechanisms and behavioral effects of opioid receptor activation is provided elsewhere Al-Hasani and Bruchas In vitro pharmacological profiling appears to be only a limited predictor of the clinical potency of opioids Baumann et al. However, rodent tail flick tests suggest mostly distinctively greater potencies of novel synthetic opioids compared with morphine Armenian et al. For example, the potency of fentanyl is reported to be to fold higher than morphine, and the potency of carfentanil is reported to be approximately 10, times higher than morphine Armenian et al. No data are currently available on monoamine transporter interactions of designer opioids. Adverse effects of novel synthetic opioids include typical symptoms of opioid overdose, such as dizziness, a lower level of consciousness, miosis, central nervous system depression, respiratory depression, pulmonary edema, hypoxia, bradycardia, pruritus, nausea, vomiting, constipation, and also such symptoms as agitation, hypertension, and tachycardia Armenian et al. Pulmonary edema, acute lung injury, diffuse alveolar hemorrhage, renal insufficiency, and rhabdomyolysis were also reported in patients who presented with designer opioid intoxication Cole et al. The synthetic opioid 1-cyclohexyl 1,2-diphenylethyl piperazine MT has been associated with bilateral hearing loss and hearing disturbances, with likely irreversible and pronounced sensorineural hearing impairment in one case Helander et al. Furthermore, acute skin and hair symptoms followed by severe delayed eye complications were reported in patients with confirmed MT use; cataract surgery was required in two of these patients Helander et al. Remaining unclear, however, is whether the aforementioned complications are solely attributable to MT toxicity. Serotonergic toxicity is one adverse effect that needs to be considered for opioid designer drugs when combined with other serotonergic agents Baldo ; Rickli et al. Similar to traditional opioids, withdrawal from designer opioids may result in physiological and psychological distress Siddiqi et al. Numerous fatalities have been attributed to either designer opioids alone or designer opioids combined with other psychoactive substances Coopman et al. Frisoni and colleagues recently published an overview of opioid-related fatalities that were attributed to synthetic opioids Frisoni et al. In addition to central nervous system and respiratory depression, chest wall rigidity after intravenous use could be a cause of death in synthetic opioid overdose cases Burns et al. The initial care of patients who are intoxicated with designer opioids should focus on airway protection and maintaining breathing and circulation Armenian et al. Naloxone should be administered as soon as possible Armenian et al. In , chlordiazepoxide became the first of several medically approved benzodiazepines that today represent a widely prescribed class of drugs for the treatment of psychiatric and neurological conditions, particularly insomnia and anxiety disorders Longo and Johnson ; Sternbach Benzodiazepine abuse is frequent. The main reasons for such abuse are to facilitate sleep, cope with stress, ease effects of stimulants, self-treat withdrawal symptoms, and get high Kapil et al. Benzodiazepines have limited potential as euphoriants when administered alone. When taken in combination with opioids, however, benzodiazepines appear to enhance the euphoric effects of opioid use Jones et al. Since , several benzodiazepine designer drugs Fig. Effects of designer benzodiazepines reported on internet forums resemble those of prescription benzodiazepines El Balkhi et al. Chronological overviews of the appearance of benzodiazepine designer drugs on the recreational drug market were recently published Manchester et al. The mechanism of action of most benzodiazepine designer drugs currently remains understudied. Benzodiazepines enhance the effects of GABA as positive allosteric modulators by binding to a receptor site that is different from the binding site of GABA Manchester et al. Despite their depressive actions on central nervous system function and respiration, the isolated use of benzodiazepines is rarely fatal. The concurrent use of benzodiazepines and other depressants, such as opioids and alcohol, may produce prolonged and potentially fatal respiratory depression Jones et al. The recent review by Zawilska and Wojcieszak mentioned the following adverse effects of designer benzodiazepines: fatigue, impairment of thinking, confusion, dizziness, drowsiness, lethargy, amnesia, blurred vision, slurred speech, palpitations, and muscle weakness, as well as auditory and visual hallucinations, delirium, seizures, deep sleep, and coma at high doses Zawilska and Wojcieszak The chronic use of designer benzodiazepines may also lead to the development of tolerance and dependence Zawilska and Wojcieszak Withdrawal symptoms, such as anxiety, panic attacks, restlessness, insomnia, seizures, and life-threatening convulsions, may follow the abrupt cessation of chronic designer benzodiazepines use Andersson and Kjellgren ; Zawilska and Wojcieszak Designer benzodiazepines have been reported to contribute to numerous deaths Bailey et al. In a few cases, the cause of death was solely attributed to the designer benzodiazepine phenazepam Crichton et al. A more detailed summary of benzodiazepine-related fatalities was recently published Zawilska and Wojcieszak It has become popular among drug users because of its ability to induce feelings of euphoria and relaxation, reduce social anxiety, and increase sexual drive Brennan and Van Hout ; Brown et al. Although it is an endogenous compound and its sodium salt is approved as a prescription drug against narcolepsy, GHB and its metabolic precursors e. Other postulated mechanisms of action include high-affinity binding to receptor sites that are distinct from the GABA B receptor i. The subjective benefits of GHB and its analogs outweigh adverse events only over a narrow range of doses. GABA B and monocarboxylate transporter inhibitors have been proposed as potential treatment options for GHB-induced respiratory depression Morse et al. GHB and its analogs are associated with the rapid development of tolerance. Zvosec and colleagues reported a series of GHB-associated deaths, of which were attributed to cardiorespiratory arrest and 13 of which were attributed to fatal accidents Zvosec et al. In approximately one-third of these fatal cases, GHB was the sole toxicant detected Zvosec et al. The co-ingestion of opioids increases the depressant toxicity of GHB, and stimulant intake does not appear to prevent GHB toxicity Knudsen et al. Dissociative agents are appreciated in medicine because of their unique pharmacological effects. These pharmacological effects, however, are also popular among recreational drug users. The dissociative anesthetic ketamine produces analgesia without cardiovascular or respiratory depression at doses that produce anesthesia, a feature that is not shared by other common anesthetics Li and Vlisides Furthermore, ketamine induces rapid and sustained antidepressant actions at a single sub-anesthetic dose and has become a widely abused recreational drug because of its dissociative effects, including sensory and tactile distortions, euphoria, and depersonalization Li and Vlisides ; Zanos and Gould Ketamine was first synthesized in as a short-acting anesthetic with lower potency in producing emergence delirium compared with the structurally similar phencyclidine PCP. PCP was developed before ketamine as a promising dissociative anesthetic, but its use in humans and animals was discontinued because of its unfavorable side effects Domino Various similar substances have been clinically investigated. Dissociatives began to appear on the illicit drug market in the late s Morris and Wallach Today, several dissociative designer drugs Fig. Morris, Wallach, and Brandt previously published comprehensive overviews of the history, availability, and use of several arylcyclohexylamine and diarylethylamine designer drugs and other dissociative agents Morris and Wallach ; Wallach and Brandt a , b. Examples of dissociative designer drugs and reference substances for comparison. Similar to ketamine and PCP, dissociative arylcyclohexylamine and diarylethylamine designer drugs act as relatively selective noncompetitive antagonists at ionotropic glutamatergic NMDA receptors. Their NMDA receptor affinity is strongly correlated with their clinical potency in inducing dissociative effects in vivo Anis et al. Some dissociative designer drugs also moderately inhibit the reuptake of norepinephrine and dopamine, whereas others have appreciable affinity for the SERT Luethi et al. Summarized, NMDA receptor antagonism mainly mediates the dissociative effects of arylcyclohexylamines and diarylethylamines, and interactions with other pharmacological targets may modify the activity of different compounds. In severe cases, dissociative designer drugs may potentially cause neurological impairment, manifested as cerebellar toxicity Shields et al. Severe adverse effects associated with inhalation of the designer drug methoxetamine include seizures, hyponatremia, and sinus bradycardia Imbert et al. Regular ketamine use has been associated with potentially irreversible bladder dysfunction and subsequent renal impairment Chu et al. Animal studies suggest that this may also be a consequence of regular methoxetamine use Dargan et al. In a survey of methoxetamine users, approximately one-fourth reported urinary symptoms Lawn et al. The prevalence of urinary symptoms was related to the frequency of methoxetamine use during the previous month, but prior ketamine use could have also contributed to these symptoms Lawn et al. Other dissociative designer drugs may also cause such severe urinary tract dysfunction, but detailed research has not been conducted. Additionally, the acute and chronic use of dissociative designer drugs potentially elicits wide-ranging effects on memory systems, similar to ketamine Morgan and Curran Dissociative designer drugs have been involved in numerous fatal intoxications, mostly in combination with other designer drugs, including stimulants, opioids, cannabinoids, and psychedelics Adamowicz and Zuba ; Bakota et al. Wallach and Brandt previously published a detailed overview of the clinical toxicology of individual PCP analogs Wallach and Brandt b and diarylethylamine- and ketamine-based designer drugs Wallach and Brandt a. The endocannabinoid system is involved in various physiological functions, including cognition, behavior, memory, motor control, pain sensation, appetite, cardiovascular parameters, gastrointestinal motility, and immunoregulation Le Boisselier et al. CB 1 receptors are mainly expressed in the brain and modulate neurotransmitter signaling, whereas CB 2 receptors are abundant in immune tissues Banister and Connor ; Le Boisselier et al. The first synthetic cannabinoids were developed in the second half of the twentieth century to study human endocannabinoid receptor systems Banister and Connor ; Le Boisselier et al. Today, synthetic cannabinoids Fig. They are commonly applied to dried herbs that mimic cannabis Banister and Connor ; Le Boisselier et al. However, compared with cannabis, synthetic cannabinoids have a less desirable effect profile and are associated with more severe adverse events that sometimes can result in death Trecki et al. CB 1 receptors are involved in multiple mechanisms that lead to the suppression of synaptic transmission. Compared with CB 2 receptor expression, the predominance of CB 1 receptors in the central nervous system indicates that they mainly mediate the psychoactive effects of synthetic cannabinoids Atwood et al. This assumption is strengthened by studies that reported that CB 1 receptor antagonism but not CB 2 receptor antagonism inhibits the synthetic cannabinoid-induced lowering of heart rate and body temperature in rodents Banister et al. In vitro studies showed that various metabolites of synthetic cannabinoids retain some cannabimimetic activity, indicating that they could contribute to the pharmacological effects of the drugs Longworth et al. In contrast, some substances that are promoted as cannabinoid designer drugs have only low in vitro affinity for cannabinoid receptors and fail to exert significant cannabinoid activity in vivo, thus calling into question their classification as synthetic cannabinoids Banister et al. Only a few synthetic cannabinoids have been studied to date with regard to their interactions with non-cannabinoid targets, with low or no affinity for most major neurotransmitter receptors Wiley et al. Furthermore, pharmacokinetic differences may contribute to these differences. The most common adverse effects of synthetic cannabinoids include agitation, drowsiness, dizziness, confusion, hallucinations, hypertension, tachycardia, chest pain, nausea, and vomiting, which typically have a short duration and require only symptomatic or supportive treatment Forrester a ; Forrester et al. Nevertheless, compared with cannabis, complications that are associated with synthetic cannabinoid use are more frequent and in some cases, more severe Alipour et al. Various severe adverse events that are associated with synthetic cannabinoids have been reported. However, many of these cases were attributed to synthetic cannabinoid use based solely on statements by patients or witnesses, without analytical confirmation of the identity and amount of substances in bodily fluids or remaining drug products. Severe clinical complications that have been reported to be associated with synthetic cannabinoid use include convulsions and seizures Adamowicz et al. Furthermore, various psychiatric adverse effects have been reported, including paranoia, psychosis, and ideations of self-harm and suicide Akram et al. The sudden discontinuation of synthetic cannabinoid use in regular. Serotonergic psychedelics induce alterations of perception and cognitive states in users Nichols , Traditional psychedelics, such as the phenethylamine 3,4,5-trimethoxyphenethylamine mescaline , the tryptamines N,N -dimethyltryptamine DMT and psilocybin, and the ergot alkaloid lysergic acid diethylamide LSD , have a history of being used for religious purposes, as therapeutic agents, and as illicit black market drugs. Although psychedelics interact with various pharmacological targets, their psychedelic effects are mainly mediated by 5-HT 2A receptor agonism Geyer and Vollenweider ; Kraehenmann et al. Designer drug analogs of all the traditional psychedelic drugs are available, some of which were originally developed by industry or university laboratories but have eventually found their way onto the illicit drug market. Correlation between reported clinical potencies and in vitro human 5-HT 2A receptor affinities of a variety of psychedelics. Derivatives of mescaline comprise a large amount of psychedelic designer drugs Fig. Psychedelic phenethylamine derivatives are mostly but not exclusively chemically modified at the phenyl ring. Examples of psychedelic phenethylamines, tryptamines, and lysergamides. Similar to other psychedelics, substituted phenethylamines mainly interact with serotonergic receptors, with the highest affinity for 5-HT 2A receptors Eshleman et al. Consistent with the in vitro findings, psychedelic phenethylamines were shown to induce 5-HT 2A -dependent behaviors in vivo, such as wet dog shakes, back muscle contractions, and a head twitch response Elmore et al. In addition to interactions with serotonergic receptors, phenethylamine psychedelics have been shown to interact with other monoaminergic targets, including adrenergic, dopaminergic, and histaminergic receptors, monoamine transporters, and MAOs Eshleman et al. However, most of these interactions are weak compared with the potent interactions with serotonergic receptors. Therefore, they most likely have little or no pharmacological relevance to the actions of phenethylamine psychedelics. Rodent studies have suggested reinforcing effects for NBOMe derivatives that involve the dopaminergic system Custodio et al. Most of the frequently reported adverse effects of phenethylamine psychedelics are shared by psychedelics of other chemical classes, including agitation, hallucinations, drowsiness, confusion, mydriasis, aggression, hyperthermia, hypertension, and tachycardia Dean et al. Moreover, severe adverse effects have been linked to the use of psychedelic phenethylamines, including acute psychosis, seizures, coma, cerebral edema, long-lasting severe neurological impairment, serotonin syndrome, prolonged respiratory failure, renal failure, multi-organ failure, metabolic acidosis, and rhabdomyolysis Bosak et al. Furthermore, 1- 4-bromofuro\[2,3- f \]\[1\]benzofuranyl propanamine Bromo-dragonFLY has been associated with potent vasoconstriction, ischemia, and tissue necrosis in patients, which may be caused by the activation of serotonergic and adrenergic receptors combined with metabolic stability and long-lasting effects Hill and Thomas ; Noble et al. A remarkable case of mass intoxication with 4-ethyl-2,5-dimethoxyphenethylamine 2C-E and Bromo-dragonFLY among 29 attendees of an esoteric weekend seminar was reported Iwersen-Bergmann et al. Upon the arrival of paramedics, some of the seminar attendees were rolling on the ground and screaming, and others were unconscious or unresponsive. Several attendees exhibited severe delusions and physical symptoms, including generalized seizures, pain, respiratory distress, and tachycardia Iwersen-Bergmann et al. In some severe cases, the use of psychedelic phenethylamines has even resulted in death Curtis et al. Adverse effects of different phenethylamine designer drugs are mostly comparable. However, a higher incidence of hallucinations, delusions, and single-episode seizures has been observed for NBOMe derivatives compared with 2C derivatives Srisuma et al. This may be explained by the higher potency of NBOMe derivatives compared with most other phenethylamine psychedelics Braden et al. Several reports have linked severe intoxication to substituted phenethylamines, but the lack of analytical confirmation of the drug prevents the direct attribution of adverse effects to phenethylamines. For example, a year-old woman was reported to have developed severe headaches, progressive encephalopathy, and quadraparesis within 48 h after taking a liquid form of 2C-B that was synthesized according to a manual on the Internet Ambrose et al. Similarly, a patient presented to an emergency department with hallucinations and agitation that progressed to status epilepticus after using of 4-chloro-2,5-dimethoxyamphetamine DOC. In addition to the analytically confirmed presence of DOC, however, the toxicology screen was positive for cannabinoids and opioids, thus hampering the attribution of seizure development to DOC Burish et al. Additionally, several fatalities from 2C derivative use have been reported in the media, but the accuracy of this information cannot be verified Dean et al. The core structure of tryptamine designer drugs contains an indole ring that is connected to an amino group by an ethyl side chain, a structural feature that is shared by 5-HT. DMT as an ingredient in the psychoactive brew ayahuasca and psilocybin that is contained in Psilocybe spp. In addition to naturally occurring compounds, psychedelic properties of various synthetic tryptamines Fig. Similar to other psychedelics, 5-HT 2A receptor agonism plays a key role in mediating the psychedelic effects of naturally occurring and synthetic tryptamine psychedelics Fantegrossi et al. Although mediating opposing functional effects on 5-HT 2A receptors, the concurrent activation of 5-HT 1A receptors has been suggested to contribute to the qualitative effects of tryptamine psychedelics, distinguishing them from phenethylamine psychedelics Fantegrossi et al. Some tryptamines are slightly more selective for one or the other receptor subtype Rickli et al. At 5-HT 2B receptors, traditional and novel tryptamine psychedelics have very heterogeneous profiles, with different potencies and efficacies. Tryptamine designer drugs have been shown to bind to 5-HT 2C receptors but with slightly lower affinity compared with 5-HT 2A receptors Rickli et al. In addition to their primary effects at serotonergic receptors, tryptamines have been shown to bind to various targets in vitro, including adrenergic, dopaminergic, and histaminergic receptors Klein et al. Furthermore, unlike phenethylamine or lysergamide psychedelics, many tryptamine psychedelics interact with monoamine transporters at pharmacologically relevant concentrations. DMT and other tryptamine psychedelics have been reported to elicit 5-HT efflux, suggesting that they are transporter substrates Blough et al. In contrast, other tryptamine psychedelics, including psilocin, act as transporter inhibitors that are devoid of substrate activity Rickli et al. In addition to interactions with transmembrane monoamine transporters, substrate activity at the VMAT has been described for tryptamine psychedelics Cozzi et al. Tryptamines are prone to metabolism by MAOs, and MAO inhibitors counteract extensive degradation of tryptamines after oral use Halberstadt et al. Similar to other psychedelics, tryptamine psychedelics alter perception and can induce psychological disturbances in users, including acute psychosis Meatherall and Sharma ; Nichols , ; Shulgin and Shulgin ; Taljemark and Johansson Adverse effects of tryptamine designer drugs include restlessness, disorientation, clouding of consciousness, confusion, hallucinations, amnesia, catalepsy, mydriasis, tachypnea, hypertension, and tachycardia Alatrash et al. In severe cases, the use of tryptamine designer drugs has resulted in acute renal failure and rhabdomyolysis Alatrash et al. Furthermore, several fatalities after the use of tryptamine designer drugs have been reported Boland et al. Several derivatives of LSD have been described in the scientific literature, and such derivatives are increasingly emerging as designer drugs Fig. Whereas self-reported effects of some LSD analogs are similar to LSD but with slightly weaker or less pleasurable effects, other LSD analogs have been reported to be distinctively less potent or significantly differ from LSD in terms of effects Coney et al. Additionally, 5-HT 1A receptor activation likely contributes to the qualitative effects of lysergamide designer drugs similarly to LSD and tryptamine psychedelics Fantegrossi et al. In addition to differences in affinity, LSD-derived designer drugs may activate 5-HT 2A receptors with lower relative potency compared with LSD, but more research is needed to test this hypothesis Brandt et al. Furthermore, unclear are the ways in which the behavioral effects of lysergamide designer drugs in animals translate to humans. Little is known about the adverse effects of lysergamide designer drugs. One case of a year-old male who developed anxiety, hallucinations, restlessness, elevations of blood pressure, palpitations, and tachycardia after ingesting 1P-LSD was reported Grumann et al. The patient reported that he recently used the stimulant phenmetrazine derivative 3-FPM. The low serum concentrations of 3-FPM that were detected at the time of hospital admission are, however, not expected to result in acute effects Grumann et al. The symptoms of this 1P-LSD intoxication case are consistent with reported adverse effects of LSD, which is known to potentially cause psychological disturbances and moderately increase body temperature, blood pressure, and heart rate Dolder et al. Acute physiological adverse effects of LSD include difficulty concentrating, imbalance, feelings of exhaustion, dizziness, headache, dry mouth, lack of appetite, and nausea Dolder et al. Nichols and Grob recently reviewed the risk of LSD toxicity in users, which they concluded was very low Nichols and Grob The few cases of fatality that were attributed to LSD toxicity were either associated with massive overdoses or physical restraint, or they were potentially caused by drugs that remained undetected in the toxicological analysis Nichols and Grob Currently, no evidence suggests that any of the currently available lysergamide designer drugs are significantly more toxic than LSD. Designer doping agents have become increasingly popular outside of the professional athletic community and include anabolic steroids, peptide hormones, growth factor mimetics, and hormone and metabolic modulators Joseph and Parr ; Poplawska and Blazewicz ; Rahnema et al. Such substances are mainly used for performance and image enhancement, exerting effects through several different mechanisms within the hormone system Graham et al. Adverse effects that are associated with performance-enhancing designer drugs include secondary hypogonadism, gynecomastia, infertility, hypertension, ischemic stroke, cardiotoxicity, hepatotoxicity, and renal failure Rahnema et al. In addition to substances that are taken to enhance athletic performance and appearance, designer drugs that are taken to enhance sexual performance, such as phosphodiesterase-5 inhibitors with no known safety profile, have also appeared. These substances may potentially induce visual disturbances or severe drug—drug interactions Venhuis et al. In addition to adverse effects that are associated with specific classes of designer drugs, some general risks are essentially the same as for traditional drugs of abuse. For example, quality assurance is not guaranteed for clandestine designer drugs. A lack of information about purity, mislabeling, pharmaceutical impurities, and hazardous cutting agents can pose a risk for drug users. A series of patients who presented to a hospital with coagulopathy and bleeding diathesis that were related to long-acting anticoagulant rodenticide adulterants of synthetic cannabinoids exemplifies their potentially fatal consequences Devgun et al. Potentially severe drug—drug interactions are a risk when more than one substance is used, including prescription medications Contrucci et al. Byproducts and impurities can pose such risks as septum perforation when insufflated or necrotic ulcers and infections when injected Lafferty et al. Hallucinogen-persisting perception disorder has been associated with psychedelics, cannabinoids, and psychostimulants, manifesting in prolonged or reoccurring perceptual symptoms Ikeda et al. The neurological and psychological changes that are associated with designer drugs can impair safe driving, and driving under the influence can severely jeopardize traffic safety Adamowicz and Lechowicz ; Maas et al. Designer drugs are often used in combination with other substances, thus hindering precise evaluations of the degree of involvement of individual substances to clinical toxicity in patients. Furthermore, designer drugs may remain undetected by routine drug screenings. Nevertheless, the pharmacological and toxicological profiles of most designer drug classes are similar to their related traditional drugs of abuse. Stimulants primarily act as substrates or inhibitors of monoamine transporters. Intoxication with stimulants mostly manifests as sympathomimetic adverse effects, the treatment of which is mainly supportive. Benzodiazepines may be given to control agitation, hypertension, and convulsions. Certain stimulants, including MDMA, have a marked serotonergic profile. Their associated adverse effects, such as serotonin syndrome, can be potentially severe clinical complications. Sedatives, including synthetic opioids and GHB analogs, pose a risk of cardiorespiratory arrest, especially when they are used in combination with other depressants, such as alcohol and benzodiazepines. Initial patient care should focus on protecting the airways and maintaining breathing and circulation. Naloxone is an effective antidote to opioid toxicity. Dissociative designer drugs act as NMDA receptor antagonists and induce adverse effects that are similar to the dissociative anesthetics ketamine and PCP. Compared with cannabis, effects of synthetic cannabinoids are less desirable, and adverse effects are more severe. Serotonergic psychedelics alter perception and cognition mainly through 5-HT 2A receptor agonism. In addition to psychological disturbances, psychedelics may induce physical adverse effects, which are usually short-lived. Rarely, designer drug use can lead to severe psychiatric and physical complications and even death. Single-drug use and more precise knowledge of substance identity, potency, and purity can reduce the risks of designer drug use. Open access funding provided by Medical University of Vienna. The authors thank Michael Arends for proofreading the manuscript. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This section collects any data citations, data availability statements, or supplementary materials included in this article. As a library, NLM provides access to scientific literature. Arch Toxicol. Find articles by Dino Luethi. Find articles by Matthias E Liechti. Received Feb 14; Accepted Feb 25; Issue date This article has been corrected. See Arch Toxicol. Open in a new tab. Supplementary file1 XLSX 38 kb Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel.

Strassen buying Ecstasy